WHO to Initiate Ebola Vaccine Trials
Published By : 27 Oct 2014 | Published By : QYRESEARCH
The World Health Organization (WHO) recently said that it is striving to speed up the human trials phase for a preventive Ebola Vaccine in West Africa. The announcement was made in a meeting at the WHO Geneva headquarters. The meeting was attended by healthcare executives and medical experts.
The trials on humans were previously believed to start in January 2015. The plans have now been pulled back a month, as stated by the WHO assistant director general for health systems and innovation, Marie-Paule Kieny. The efforts made by all bodies involved in the process and its speeding up have been described. She also said that developing a vaccine is a long and difficult process. However once the vaccines are ready to be administered, they have and important job of eliminating the epidemic.
Currently, a number of vaccines are available for Ebola, but all exist on an experimental basis. They cannot be distributed and administered on a wide scale until they are proven safe through tests for human safety, effectiveness in boosting the body’s defenses, and immunogenicity.
The companies currently in the forerunning for creating an Ebola vaccine are NewLink Genetics Corp., GlaxoSmithKline plc, and Johnson & Johnson. The first to start human trials was GSK, who initiated the trials in the U.S. and the U.K. in September. Their African trials began in Mali in early October. NewLink started human trials in Maryland last week.
Who also tested vaccines by other companies including Inovio Pharmaceuticals Inc., Hemispherx BioPharma Inc., and NanoViricides Inc.